Cargando…

Impact of apremilast on quality of life in Behçet’s syndrome: analysis of the phase 3 RELIEF study

OBJECTIVE: To assess apremilast’s impact on patient quality of life (QoL) in active Behçet’s syndrome and correlations between improvement in patients’ QoL and efficacy measures in the phase 3 RELIEF study. METHODS: QoL measures included Behçet’s Disease QoL (BDQoL), 36-Item Short-Form Health Survey...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hatemi, Gülen, Mahr, Alfred, Takeno, Mitsuhiro, Kim, Doyoung, Melikoğlu, Melike, Cheng, Sue, McCue, Shannon, Paris, Maria, Chen, Mindy, Yazici, Yusuf
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2022
Materias:	Vasculitis
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9263903/ https://www.ncbi.nlm.nih.gov/pubmed/35798511 http://dx.doi.org/10.1136/rmdopen-2022-002235

Ejemplares similares

Development and preliminary validation of the Behçet’s syndrome Overall Damage Index (BODI)
por: Piga, Matteo, et al.
Publicado: (2020)

Systematic literature review informing the 2018 update of the EULAR recommendation for the management of large vessel vasculitis: focus on giant cell arteritis
por: Monti, Sara, et al.
Publicado: (2019)

Management of Takayasu arteritis: a systematic literature review informing the 2018 update of the EULAR recommendation for the management of large vessel vasculitis
por: Águeda, Ana F, et al.
Publicado: (2019)

Validation of the EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis by disease content experts
por: Yates, Max, et al.
Publicado: (2017)

The association of Behçet's syndrome with HLA-B51 as understood in 2021
por: Takeno, Mitsuhiro
Publicado: (2022)

Quantiferon-TB Gold in tube assay for the screening of tuberculosis before and during treatment with tumor necrosis factor alpha antagonists
por: Hatemi, Gulen, et al.
Publicado: (2012)

Identification of Functional and Expression Polymorphisms Associated With Risk for Antineutrophil Cytoplasmic Autoantibody–Associated Vasculitis
por: Merkel, Peter A., et al.
Publicado: (2017)

Apremilast Long-Term Safety Up to 5 Years from 15 Pooled Randomized, Placebo-Controlled Studies of Psoriasis, Psoriatic Arthritis, and Behçet’s Syndrome
por: Mease, Philip J., et al.
Publicado: (2023)

Phase IIa Global Study Evaluating Rituximab for the Treatment of Pediatric Patients With Granulomatosis With Polyangiitis or Microscopic Polyangiitis
por: Brogan, Paul, et al.
Publicado: (2021)

Glucocorticoid Dosages and Acute‐Phase Reactant Levels at Giant Cell Arteritis Flare in a Randomized Trial of Tocilizumab
por: Stone, John H., et al.
Publicado: (2019)

Efficacy and safety of mavrilimumab in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial
por: Cid, Maria C, et al.
Publicado: (2022)

Tocilizumab is effective against polymyalgia rheumatica: experience in 13 intractable cases
por: Izumi, Keisuke, et al.
Publicado: (2015)

Accuracy of musculoskeletal imaging for the diagnosis of polymyalgia rheumatica: systematic review
por: Mackie, Sarah Louise, et al.
Publicado: (2015)

PTPN22 R620W minor allele is a genetic risk factor for giant cell arteritis
por: Lester, Susan, et al.
Publicado: (2016)

Balancing on the edge: implications of a UK national audit of the use of BSR-BHPR guidelines for the diagnosis and management of polymyalgia rheumatica
por: Das, Parthajit, et al.
Publicado: (2015)

Long-term efficacy and safety of tocilizumab in giant cell arteritis and large vessel vasculitis
por: Evans, Jobie, et al.
Publicado: (2016)

Geo-epidemiology of temporal artery biopsy-positive giant cell arteritis in Australia and New Zealand: is there a seasonal influence?
por: De Smit, Elisabeth, et al.
Publicado: (2017)

Definitions and reliability assessment of elementary ultrasound lesions in giant cell arteritis: a study from the OMERACT Large Vessel Vasculitis Ultrasound Working Group
por: Chrysidis, Stavros, et al.
Publicado: (2018)

Long-term patient survival in a Swedish population-based cohort of patients with ANCA-associated vasculitis
por: Heijl, Caroline, et al.
Publicado: (2017)

Serum osteopontin: a biomarker of disease activity and predictor of relapsing course in patients with giant cell arteritis. Potential clinical usefulness in tocilizumab-treated patients
por: Prieto-González, Sergio, et al.
Publicado: (2017)

Association between glucocorticoid therapy and incidence of diabetes mellitus in polymyalgia rheumatica and giant cell arteritis: a systematic review and meta-analysis
por: Lai, Lana Yin Hui, et al.
Publicado: (2018)

Efficacy and Safety of Belimumab and Azathioprine for Maintenance of Remission in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis: A Randomized Controlled Study
por: Jayne, David, et al.
Publicado: (2019)

T-lymphocyte in ANCA-associated vasculitis: what do we know? A pathophysiological and therapeutic approach
por: Martinez Valenzuela, Laura, et al.
Publicado: (2019)

Treatment of polyarteritis nodosa with tocilizumab: a new therapeutic approach?
por: Saunier, Aurélie, et al.
Publicado: (2017)

Is vascular endothelial growth factor a useful biomarker in giant cell arteritis?
por: Goodfellow, Nicola, et al.
Publicado: (2017)

Modified-release prednisone for polymyalgia rheumatica: a multicentre, randomised, active-controlled, double-blind, parallel-group study
por: Cutolo, Maurizio, et al.
Publicado: (2017)

Rituximab as therapy to induce remission after relapse in ANCA-associated vasculitis
por: Smith, Rona M, et al.
Publicado: (2020)

Vascular ultrasound for the diagnosis of giant cell arteritis: a reliability and agreement study based on a standardised training programme
por: Chrysidis, Stavros, et al.
Publicado: (2020)

Probability-based algorithm using ultrasound and additional tests for suspected GCA in a fast-track clinic
por: Sebastian, Alwin, et al.
Publicado: (2020)

Cardiovascular drug treatment, statins and biopsy-confirmed giant cell arteritis: a population-based case–control study
por: Turkiewicz, Aleksandra, et al.
Publicado: (2020)

Efficacy of mycophenolate mofetil as a remission induction therapy in antineutrophil cytoplasmic antibody-associated vasculitis—a meta-analysis
por: Kuzuya, Kentaro, et al.
Publicado: (2020)

Efficacy and safety of rituximab in the treatment of eosinophilic granulomatosis with polyangiitis
por: Teixeira, Vítor, et al.
Publicado: (2019)

Association of Pulmonary Hemorrhage, Positive Proteinase 3, and Urinary Red Blood Cell Casts With Venous Thromboembolism in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis
por: Kronbichler, Andreas, et al.
Publicado: (2019)

Efficacy and safety of tocilizumab in giant cell arteritis: a single centre NHS experience using imaging (ultrasound and PET-CT) as a diagnostic and monitoring tool
por: Sebastian, Alwin, et al.
Publicado: (2020)

ANCA-associated renal vasculitis is associated with rurality but not seasonality or deprivation in a complete national cohort study
por: Aiyegbusi, Oshorenua, et al.
Publicado: (2021)

Long‐Term Safety of Rituximab in Granulomatosis With Polyangiitis and in Microscopic Polyangiitis
por: Merkel, Peter A., et al.
Publicado: (2021)

Treatment failure in giant cell arteritis
por: Unizony, Sebastian H, et al.
Publicado: (2021)

Novel aspects of regulatory T cell dysfunction as a therapeutic target in giant cell arteritis
por: Adriawan, Ignatius Ryan, et al.
Publicado: (2022)

Need and value of targeted immunosuppressive therapy in giant cell arteritis
por: Sandovici, Maria, et al.
Publicado: (2022)

Eosinophilic granulomatosis with polyangiitis exhibits T cell activation and IgG4 immune response in the tissue; comparison with IgG4-related disease
por: Kubo, Satoshi, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_s1072c5iga6u4am2d8nh782gb6